铂类治疗后转移性尿路上皮癌接受PD-L1抑制剂生存的五因素预后模型
研究利用阿替利珠单抗的2项Ⅰ/Ⅱ期试验(405例)构建预后模型,并在阿维鲁单抗(242例)和度伐利尤单抗(198例)试验中验证。识别出ECOG-PS、肝转移、血小板计数、中性粒细胞与淋巴细胞比值和乳酸脱氢酶5个预后因素,模型区分度良好,c-statistic在推导集为0.692,验证集分别为0.671和0.773。
要点
- 5个预后因素:ECOG-PS、肝转移、血小板计数、NLR和LDH。
- 模型在三种PD-L1抑制剂中验证,区分度满意。
- 基于风险因素开发了在线工具计算预期生存概率。
核心结论
- 验证的5因素模型对铂类治疗后转移性尿路上皮癌接受PD-L1抑制剂的生存预后性能满意,可辅助分层、解读和设计试验。
研究设计与样本
- 使用阿替利珠单抗的2项Ⅰ/Ⅱ期试验(405例)作为推导数据集,阿维鲁单抗(242例)和度伐利尤单抗(198例)的2项Ⅰ/Ⅱ期试验作为验证数据集。
- 采用Cox回归分析候选预后因素与总生存的关联,逐步选择法构建最优模型,并在验证集中评估区分度和校准度。
主要发现
- 最优模型识别的5个预后因素为:ECOG-PS(1 vs 0,HR 1.80,95%CI 1.36-2.36)、肝转移(HR 1.55,95%CI 1.20-2.00)、血小板计数(HR 2.22,95%CI 1.54-3.18)、中性粒细胞与淋巴细胞比值(HR 1.94,95%CI 1.57-2.40)和乳酸脱氢酶(HR 1.60,95%CI 1.28-1.99)。
- 低、中、高风险组间生存区分度稳健。
- c-statistic在推导集为0.692,在阿维鲁单抗和度伐利尤单抗验证集中分别为0.671和0.773。
- 开发了基于风险因素计算预期生存概率的网页交互工具。
临床怎么用
- 该模型可用于铂类治疗后转移性尿路上皮癌接受PD-L1抑制剂治疗的患者风险分层,辅助临床决策和试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing models were constructed in the chemotherapy setting. MATERIALS AND METHODS: Patient level data were used from phase I/II trials evaluating PD-L1 inhibitors following platinum based chemotherapy for metastatic urothelial carcinoma. The derivation data set consisted of 2 phase I/II trials evaluating atezolizumab (405). Two phase I/II trials that evaluated avelumab (242) and durvalumab (198) comprised the validation data sets. Cox regression analyses evaluated the association of candidate prognostic factors with overall survival. Stepwise selection was used to select an optimal model using the derivation data set. Discrimination and calibration were assessed in the avelumab and durvalumab data sets. RESULTS: The 5 prognostic factors identified in the optimal model using the atezolizumab derivation data set were ECOG-PS (1 vs 0, HR 1.80, 95% CI 1.36-2.36), liver metastasis (HR 1.55, 95% CI 1.20-2.00), platelet count (HR 2.22; 95% CI 1.54-3.18), neutrophil-to-lymphocyte ratio (HR 1.94, 95% CI 1.57-2.40) and lactate dehydrogenase (HR 1.60, 95% CI 1.28-1.99). There was robust discrimination of survival between low, intermediate and high risk groups. The c-statistic was 0.692 in the derivation and 0.671 and 0.773 in the avelumab and durvalumab validation data sets, respectively. A web based interactive tool was developed to calculate the expected survival probabilities based on risk factors. CONCLUSIONS: A validated 5-factor model has satisfactory prognostic performance for survival across 3 PD-L1 inhibitors to treat metastatic urothelial carcinoma after platinum therapy and may assist in stratification, interpreting and designing trials incorporating PD-1/PD-L1 inhibitors in the post-platinum setting.
引用
- Sonpavde G, Manitz J, Gao C, et al. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. J Urol. 2020. PMID: 32552295. doi:10.1097/JU.0000000000001199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。